200 related articles for article (PubMed ID: 10219982)
1. Human CRF2 alpha and beta splice variants: pharmacological characterization using radioligand binding and a luciferase gene expression assay.
Ardati A; Goetschy V; Gottowick J; Henriot S; Valdenaire O; Deuschle U; Kilpatrick GJ
Neuropharmacology; 1999 Mar; 38(3):441-8. PubMed ID: 10219982
[TBL] [Abstract][Full Text] [Related]
2. 125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors.
Grigoriadis DE; Liu XJ; Vaughn J; Palmer SF; True CD; Vale WW; Ling N; De Souza EB
Mol Pharmacol; 1996 Sep; 50(3):679-86. PubMed ID: 8794910
[TBL] [Abstract][Full Text] [Related]
3. Autoradiographic localization of CRF1 and CRF2 binding sites in adult rat brain.
Primus RJ; Yevich E; Baltazar C; Gallager DW
Neuropsychopharmacology; 1997 Nov; 17(5):308-16. PubMed ID: 9348546
[TBL] [Abstract][Full Text] [Related]
4. Characterization of [125I]sauvagine binding to CRH2 receptors: membrane homogenate and autoradiographic studies.
Rominger DH; Rominger CM; Fitzgerald LW; Grzanna R; Largent BL; Zaczek R
J Pharmacol Exp Ther; 1998 Jul; 286(1):459-68. PubMed ID: 9655891
[TBL] [Abstract][Full Text] [Related]
5. Distribution of corticotropin-releasing factor (CRF) receptor binding in the mouse brain using a new, high-affinity radioligand, [
Tan LA; Vaughan JM; Perrin MH; Rivier JE; Sawchenko PE
J Comp Neurol; 2017 Dec; 525(18):3840-3864. PubMed ID: 28842924
[TBL] [Abstract][Full Text] [Related]
6. Structure and function of the ovine type 1 corticotropin releasing factor receptor (CRF1) and a carboxyl-terminal variant.
Myers DA; Trinh JV; Myers TR
Mol Cell Endocrinol; 1998 Sep; 144(1-2):21-35. PubMed ID: 9863624
[TBL] [Abstract][Full Text] [Related]
7. Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications.
McCarthy JR; Heinrichs SC; Grigoriadis DE
Curr Pharm Des; 1999 May; 5(5):289-315. PubMed ID: 10213797
[TBL] [Abstract][Full Text] [Related]
8. Labelling of CRF1 and CRF2 receptors using the novel radioligand, [3H]-urocortin.
Gottowik J; Goetschy V; Henriot S; Kitas E; Fluhman B; Clerc RG; Moreau JL; Monsma FJ; Kilpatrick GJ
Neuropharmacology; 1997 Oct; 36(10):1439-46. PubMed ID: 9423932
[TBL] [Abstract][Full Text] [Related]
9. Expression and characterisation of human and rat CRF2alpha receptors.
Suman-Chauhan N; Carnell P; Franks R; Webdale L; Gee NS; McNulty S; Rossant CJ; Van Leeuwen D; MacKenzie R; Hall MD
Eur J Pharmacol; 1999 Aug; 379(2-3):219-27. PubMed ID: 10497909
[TBL] [Abstract][Full Text] [Related]
10. Development of a selective photoactivatable antagonist for corticotropin-releasing factor receptor, type 2 (CRF2).
Bonk I; Rühmann A
Eur J Biochem; 2002 Nov; 269(21):5288-94. PubMed ID: 12392562
[TBL] [Abstract][Full Text] [Related]
11. Peptide ligand binding properties of the corticotropin-releasing factor (CRF) type 2 receptor: pharmacology of endogenously expressed receptors, G-protein-coupling sensitivity and determinants of CRF2 receptor selectivity.
Hoare SR; Sullivan SK; Fan J; Khongsaly K; Grigoriadis DE
Peptides; 2005 Mar; 26(3):457-70. PubMed ID: 15652653
[TBL] [Abstract][Full Text] [Related]
12. Evidence for the abundant expression of arginine 185 containing human CRF(2alpha) receptors and the role of position 185 for receptor-ligand selectivity.
Dautzenberg FM; Huber G; Higelin J; Py-Lang G; Kilpatrick GJ
Neuropharmacology; 2000 Jun; 39(8):1368-76. PubMed ID: 10818253
[TBL] [Abstract][Full Text] [Related]
13. Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain.
Sánchez MM; Young LJ; Plotsky PM; Insel TR
J Comp Neurol; 1999 Jun; 408(3):365-77. PubMed ID: 10340512
[TBL] [Abstract][Full Text] [Related]
14. The ligand-selective domains of corticotropin-releasing factor type 1 and type 2 receptor reside in different extracellular domains: generation of chimeric receptors with a novel ligand-selective profile.
Dautzenberg FM; Kilpatrick GJ; Wille S; Hauger RL
J Neurochem; 1999 Aug; 73(2):821-9. PubMed ID: 10428081
[TBL] [Abstract][Full Text] [Related]
15. Functional, endogenously expressed corticotropin-releasing factor receptor type 1 (CRF1) and CRF1 receptor mRNA expression in human neuroblastoma SH-SY5Y cells.
Schoeffter P; Feuerbach D; Bobirnac I; Gazi L; Longato R
Fundam Clin Pharmacol; 1999; 13(4):484-9. PubMed ID: 10456290
[TBL] [Abstract][Full Text] [Related]
16. Characterisation using microphysiometry of CRF receptor pharmacology.
Smart D; Coppell A; Rossant C; Hall M; McKnight AT
Eur J Pharmacol; 1999 Aug; 379(2-3):229-35. PubMed ID: 10497910
[TBL] [Abstract][Full Text] [Related]
17. Conformational states of the corticotropin releasing factor 1 (CRF1) receptor: detection, and pharmacological evaluation by peptide ligands.
Hoare SR; Sullivan SK; Pahuja A; Ling N; Crowe PD; Grigoriadis DE
Peptides; 2003 Dec; 24(12):1881-97. PubMed ID: 15127940
[TBL] [Abstract][Full Text] [Related]
18. Different binding modes of amphibian and human corticotropin-releasing factor type 1 and type 2 receptors: evidence for evolutionary differences.
Dautzenberg FM; Py-Lang G; Higelin J; Fischer C; Wright MB; Huber G
J Pharmacol Exp Ther; 2001 Jan; 296(1):113-20. PubMed ID: 11123370
[TBL] [Abstract][Full Text] [Related]
19. [¹²⁵I]YP20: a novel radioligand specific for the extracellular domain of the CRF₁ receptor.
Gordon JC; Edwards P; Elmore CS; Lazor LA; Paschetto K; Bostwick R; Sylvester M; Mauger R; Scott C; Aharony D
Eur J Pharmacol; 2010 Dec; 649(1-3):59-63. PubMed ID: 20854803
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a Pachymedusa dacnicolor-Sauvagine analog as a new high-affinity radioligand for corticotropin-releasing factor receptor studies.
Perrin MH; Tan LA; Vaughan JM; Lewis KA; Donaldson CJ; Miller C; Erchegyi J; Rivier JE; Sawchenko PE
J Pharmacol Exp Ther; 2015 May; 353(2):307-17. PubMed ID: 25736419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
